Market Overview

MLV & Co Reiterates Buy, $4.50 PT on ImmunoCellular Therapeutics on Move to NYSE

Related IMUC
5 Companies Developing New Cancer Drugs
Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower

MLV & Co reiterates its Buy rating with a $4.50 price target on ImmunoCellular Therapeutics (NYSE: IMUC) as the company gets its listing on the NYSE starting next week.

MLV & Co comments, "We view this move as an affirmation of the company's commitment to growing their pipeline, and providing opportunities for their investors. The move also signals to us that the company is confident in its business model moving forward. ImmunoCellular operates on a cost-efficiency basis of collaboration and outsourcing of product development and clinical trial management."

IMUC closed at $2.82 on Thursday.

Posted-In: MLV & CoAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (IMUC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters